Molnlycke has announced a new collaboration with Scottish Enterprise focused on combating the spread of superbugs in healthcare settings.
The company has signed an agreement to develop products based on an innovative technology platform shown to deliver rapid results in detecting antibiotic-resistant bacteria.
Developed in collaboration with the University of Edinburgh, the technology utilises electrochemical impedance spectroscopy to detect and quantify biomarkers showing the presence of dangerous pathogens such as MRSA.
Current methods of screening for these strains can take up to 48 hours, during which time infections can quickly spread between patients and healthcare workers.
Pierre Guyot, chief executive officer at Molnlycke Health Care, said: "We are very proud to be extending our offering of efficient infection control and prevention solutions that make life easier and safer for healthcare professionals and patients."
Last month, the company supported Stop Pressure Ulcer Awareness Day, an event designed to increase understanding of the physical and mental impact of pressure ulcers.See all the latest jobs in Medical Devices